Medindia

X

Nasal Mucosal Inhalation of Alzheimer's Disease Vaccine Attenuates Aβ1-42-induced Cytotoxicity

by Bidita Debnath on  July 12, 2014 at 10:13 PM Research News   - G J E 4
N-methyl-D-aspartate receptor antagonists and cholinergic inhibitors can alleviate the symptoms of Alzheimer's disease.
 Nasal Mucosal Inhalation of Alzheimer's Disease Vaccine Attenuates Aβ1-42-induced Cytotoxicity
Nasal Mucosal Inhalation of Alzheimer's Disease Vaccine Attenuates Aβ1-42-induced Cytotoxicity
Advertisement

But it fails to affect irreversible cognitive dysfunction and effectively scavenge amyloid beta peptide in the brain. Amyloid beta peptide (Aβ) vaccines reduced and eliminated Aβ deposition in an Alzheimer's disease (AD) transgenic mouse model, and significantly improved behavioral and cognitive impairment.

Advertisement
Dr. Yunpeng Cao and his team, First Affiliated Hospital of China Medical University, China immunized AD transgenic mouse models with Plp-Adeno-X-CMV-(Aβ3-10)10-CpG via nasal mucosal inhalation. They found that Plp-Adeno-X-CMV-(Aβ3-10)10-CpG vaccine can produce strong T helper 2 humoral immune responses, and avoid Aβ1-42-caused T helper 1 immune responses and Aβ1-42-induced cytotoxicity.

Therefore, Plp-Adeno-X-CMV-(Aβ3-10)10-CpG vaccine can be used as a novel type of AD vaccine. These findings were published in Neural Regeneration Research (Vol. 9, No. 8, 2014).

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like